In a letter to the Federal Trade Commission (FTC), the AAI today outlined the competitive concerns raised by the proposed merger of generic pharmaceutical makers Teva and Allergan. The letter was written by AAI Advisor Bill Comanor, Professor, Department of Economics, University of California, Santa Barbara and Professor, Department of Health Policy and Management, University of California, Los Angeles, and AAI President Diana Moss
One of American history’s most notorious battles over a Supreme Court appointment occurred one hundred years ago, when President Woodrow Wilson nominated Louis D. Brandeis to the US Supreme Court. Whether the conservative opposition was merely anti-Progressive (Brandeis being a key designer and advocate of Progressive politics, with Wilson’s ear), anti-Semitic, or some combination, may not make much difference today. Brandeis was in fact relatively conservative in his private life, even a prude by some measures, and he had built himself into one of the wealthiest private lawyers in the nation, serving many corporate clients.
Last week, the American Antitrust Institute (AAI) published an open letter to DOJ Antitrust Division Chief Bill Baer, urging the Division to "just say no" to the proposed mergers of Aetna/Humana and Anthem/Cigna. On Wednesday, January 20 at 2 p.m. ET, The Capitol Forum will host a conference call with AAI President Diana Moss and AAI Advisor Tim Greaney to discuss the letter, as well as their views of the proposed managed care deals' potential competitive implications.
In a letter to the U.S. Department of Justice (DOJ) Antitrust Division, the AAI today outlined the myriad competitive and consumer concerns surrounding the proposed health insurance mergers of Aetna-Humana and Anthem-Cigna. The letter was written by AAI Advisor Tim Greaney, Chester A. Myers Professor and Co-Director, Center for Health Law Studies at the Saint Louis University School of Law, and AAI President Diana Moss.
Today, Chairman of the American Antitrust Institute (AAI) Board of Director Robert Skitol announced the addition of Roberta D. Liebenberg to the Board.